AndrewC.IpMDMSc
Oncology • Hackensack, NJHematologic Oncology
Division of Lymphoma Outcomes and Value Based Care Division
Overview of Dr. Ip
As chief of the Outcomes and Value Care Division and a member of the Division of Lymphoma at John Theurer Cancer Center, I lead the center’s outcomes and values care research effort. My focus is on reviewing data about cancer patients across the Hackensack Meridian Health system to understand how to achieve the best patient outcomes as well as value from their outcome, whether it be cost or improved quality of life.
Office
92 2nd Street
Hackensack, NJ 07601- Is this information wrong?
Education & Training
Emory University, Laney Graduate SchoolMSc, Clinical research, 2017 - 2019
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2016 - 2019- Emory University School of MedicineResidency, Internal Medicine, 2012 - 2015
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2012
Certifications & Licensure
NJ State Medical License 2019 - 2025
GA State Medical License 2014 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- EPR24-110: Prior SARS-CoV-2 in Patients With CAR-T Negatively Impacts Overall Survival, Highlighting the Need for Targeted Prophylaxis Strategies.Simi Aggarwal, Yuval Koren, Dan Poscover, Cátia Ferreira, Lisa Glasser, Kathleen Heil, Della Varghese, Sudhir Venkatesan, Carla Talarico, Andrew Ip> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
- SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle...Alexandra Della Pia, Andrew Ip, Andre H Goy> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 22
- 3 citationsIdentifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.Michael Scordo, Jessica R Flynn, Mithat Gonen, Sean M Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L Porter, Stephen J Schuster, ...> ;Blood Advances. 2023 Sep 26
- Join now to see all
Journal Articles
- Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyNoa Biran, Andrew Ip, Ronaldo Collo Go, The Lancet Rheumatology
Authored Content
- Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyAugust 2020
- Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyAugust 2020
Press Mentions
New Model Can Help Clinicians to Predict 40-Day Mortality Risk in Hospitalized COVID-19 PatientsAugust 2nd, 2021- Diagnosis, Clinical Characteristics, and Outcomes of COVID-19 Patients from a Large Healthcare System in Northern New JerseyFebruary 23rd, 2021
- Yale Doctor Slams Fauci for His Dismissal of Hydroxychloroquine in COVID TreatmentFebruary 1st, 2021
- Join now to see all
Hospital Affiliations
Hackensack Meridian Health Hackensack University Medical CenterHackensack, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
